Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

MiNK Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$11.34

-0.53 (-4.47%)

F 15Pipeline Score Biotech · Pre-Clinical
Market Cap
54.15 M
EPS
-2.84
P/E Ratio
-
Value Trade
472.40 K
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • R&D Expenses

    1.20 M

  • Operating CF

    -1.73 M

  • Total Assets

    10.38 M

  • Total Liabilities

    10.38 M

  • Equity

    -12.69 M

  • D/E Ratio

    12,345

-1.98 %
Week
-8.66 %
1 Month
-2.95 %
3 Month
2.45 %
6 Month
-90.97 %
5 Year
-90.97 %
All Time
Cash Data
Stable

  • Cash Position

    9.53 M

  • Monthly Burn

    578.00 K

  • Runway

    15.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
21.58 K
52 Week Range
6.80 - 76
% held by Insiders
61.25 %
% held by Institutions
2.53 %
Enterprise Value
44.63 M
Total Shares
4.70 M
Short %
6.37 %
Float Shares
1.16 M
Company Description
HQ: 149 FIFTH AVENUE, NEW YORK, NY...
Employees:15
https://www.minktherapeutics.c...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
agenT-797 hypoxemic pneumonia/ARDS
Phase 2
—
-
-
agenT-797 hypoxemic pneumonia/ARDS
Phase 2
—
-
-
agenT-797 hypoxemic pneumonia/ARDS
Phase 2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
F15
Pipeline Score
-
Pipeline Value
Valuation Signal
0
Drugs Scored
—
rNPV / MCap
Top 11%
Micro Cap
(rank 806 of 905)
Percentile Rank
MiNK Therapeutics, Inc. has significant pipeline risk (15/100).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
agenT-797
Small molecule		Respiratory Distress Syndrome, AdultPhase 1NCT045822017% $557M -20 - -— - -
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
agenT-797
testicular cancer,gastric cancer
Phase 2
2025-07-14
agenT-797
testicular cancer,gastric cancer
Phase 2
2025-07-14
agenT-797
testicular cancer,gastric cancer
Phase 2
2025-07-14
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in INKT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
MiNK Therapeutics, Inc. (INKT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
INKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
INKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
INKT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
INKT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
INKT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest MiNK Therapeutics, Inc. (INKT) News & Alerts
-
Tuesday, June 9, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How INKT ranks across every disease it competes in
No competitive intelligence available for INKT.